Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Rita, Yim"'
Autor:
Harinder Gill, Radha Raghupathy, Carmen Y.Y. Lee, Yammy Yung, Hiu-Tung Chu, Michael Y. Ni, Xiao Xiao, Francis P. Flores, Rita Yim, Paul Lee, Lynn Chin, Vivian W.K. Li, Lester Au, Wing-Yan Au, Edmond S.K. Ma, Diwakar Mohan, Cyrus Rustam Kumana, Yok-Lam Kwong
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Background The epidemiology and treatment of acute promyelocytic leukaemia (APL) are changing. We have incorporated oral arsenic trioxide (oral-ATO) into induction/maintenance. Methods Newly-diagnosed APL from 1991 to 2021 divided into three
Externí odkaz:
https://doaj.org/article/c6e19c5014b74121914b1a74c9edba0a
Autor:
Harry Gill, Rita Yim, Lynn Chin, Paul Lee, Vivian LI, Lester Au, Man Kit Garret Leung, Cyrus Kumana, Yok Lam Kwong
Publikováno v:
HemaSphere, Vol 7, p e462409a (2023)
Externí odkaz:
https://doaj.org/article/9da061492d194913827c1016cc504f37
Autor:
Harry Gill, Lester Au, Dorothy Tsai, Man Kit Garret Leung, Rita Yim, Lynn Chin, Vivian LI, Paul Lee, Chung Fung Albert Sin, Hsin-An Hou, Chih-Cheng Chen, Yok Lam Kwong
Publikováno v:
HemaSphere, Vol 7, p e9247372 (2023)
Externí odkaz:
https://doaj.org/article/136e80a05f364270a52c3cc625d03286
Autor:
Harry Gill, Radha Raghupathy, Hsin-An Hou, Adisak Tantiworawit, Melissa G. Ooi, Priscella S. Chia, Gin Gin Gan, Chieh-Lee Wong, Lynn Chin, Rita Yim, Paul Lee, Lester Au, Vivian LI, Man Kit Garret Leung, Wee Joo Chng, Wen Chien Chou, Hwei-Fang Tien, Cyrus Kumana, Yok Lam Kwong
Publikováno v:
HemaSphere, Vol 7, p e6159196 (2023)
Externí odkaz:
https://doaj.org/article/cb5a2839eb8846ea9ee3910ca09b0e8e
Autor:
Harinder Gill, Rita Yim, Herbert H. Pang, Paul Lee, Thomas S. Y. Chan, Yu‐Yan Hwang, Garret M. K. Leung, Ho‐Wan Ip, Rock Y. Y. Leung, Sze‐Fai Yip, Bonnie Kho, Harold K. K. Lee, Vivien Mak, Chi‐Chung Chan, June S. M. Lau, Chi‐Kuen Lau, Shek‐Yin Lin, Raymond S. M. Wong, Wa Li, Edmond S. K. Ma, Jun Li, Gianni Panagiotou, Joycelyn P. Y. Sim, Albert K. W. Lie, Yok‐Lam Kwong
Publikováno v:
Cancer Medicine, Vol 9, Iss 10, Pp 3371-3382 (2020)
Abstract Clofarabine is active in refractory/relapsed acute myeloid leukemia (AML). In this phase 2 study, we treated 18‐ to 65‐year‐old AML patients refractory to first‐line 3 + 7 daunorubicin/cytarabine induction or relapsing after 3 + 7 in
Externí odkaz:
https://doaj.org/article/2744c5249b7a4f84a43188e34f729a01
Autor:
Paul Lee, Rita Yim, Kai-Kei Miu, Sin-Hang Fung, Jason Jinyue Liao, Zhangting Wang, Jun Li, Yammy Yung, Hiu-Tung Chu, Pui-Kwan Yip, Emily Lee, Eric Tse, Yok-Lam Kwong, Harinder Gill
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 10, p 5670 (2022)
In myelodysplastic syndrome (MDS), resistance to hypomethylating agents (HMA) portends a poor prognosis, underscoring the importance of understanding the molecular mechanisms leading to HMA-resistance. In this study, P39 and Kasumi-1 cells and their
Externí odkaz:
https://doaj.org/article/242f13a9adea43ac815fe4e8db79d843
Autor:
Paul Lee, Rita Yim, Sin-Hang Fung, Kai-Kei Miu, Zhangting Wang, Ka-Chun Wu, Lester Au, Garret Man-Kit Leung, Victor Ho-Fun Lee, Harinder Gill
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 9, p 4647 (2022)
Myelodysplastic syndrome (MDS) is a clonal myeloid neoplasm characterized by ineffective hematopoiesis, cytopenia, dysplasia, and clonal instability, leading to leukemic transformation. Hypomethylating agents are the mainstay of treatment in higher-r
Externí odkaz:
https://doaj.org/article/87e11914ef9747cb8f7dc97cc0553dc2
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 19, p 10232 (2021)
Myelodysplastic syndrome (MDS) is a heterogeneous, clonal hematological disorder characterized by ineffective hematopoiesis, cytopenia, morphologic dysplasia, and predisposition to acute myeloid leukemia (AML). Stem cell genomic instability, microenv
Externí odkaz:
https://doaj.org/article/49957e78d51d445c9d79e1480660006f
Autor:
Harinder Gill, Radha Ragupathy, Carmen Y.Y. Lee, Yammy Yung, Hiu-Tung Chu, Michael Ni, Xiao Xiao, Francis P Flores, Rita Yim, Paul Lee, Lynn Chin, Vivian W.K. Li, Lester Au, Wing-Yan Au, Edmond S.K. Ma, Diwakar Mohan, Cyrus R Kumana, Yok-Lam Kwong
BackgroundThe epidemiology and treatment of acute promyelocytic leukaemia (APL) are changing. We have incorporated oral arsenic trioxide (oral-ATO) into induction/maintenance.MethodsNewly-diagnosed APL from 1991 to 2021 divided into three 10-year per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02e0a4a7ed250df58f0692ee93e8a071
https://doi.org/10.21203/rs.3.rs-1610362/v1
https://doi.org/10.21203/rs.3.rs-1610362/v1
Autor:
Paul, Lee, Rita, Yim, Kai-Kei, Miu, Sin-Hang, Fung, Jason Jinyue, Liao, Zhangting, Wang, Jun, Li, Yammy, Yung, Hiu-Tung, Chu, Pui-Kwan, Yip, Emily, Lee, Eric, Tse, Yok-Lam, Kwong, Harinder, Gill
Publikováno v:
International journal of molecular sciences. 23(10)
In myelodysplastic syndrome (MDS), resistance to hypomethylating agents (HMA) portends a poor prognosis, underscoring the importance of understanding the molecular mechanisms leading to HMA-resistance. In this study, P39 and Kasumi-1 cells and their